Search Result

Results for "

CD3+

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Kit (3) CD19 (4) CD2 (1) CD20 (8) CD22 (1) CD28 (4) CD3 (96) CD38 (4) CD44 (1) CTLA-4 (1) FLT3 (2) 5-HT Receptor (11) Acetolactate Synthase (ALS) (1) ADC Payload (2) Adenosine Receptor (1) Adrenergic Receptor (8) Akt (1) Amino Acid Derivatives (1) Androgen Receptor (3) Angiotensin Receptor (1) Antibiotic (18) Apoptosis (25) Aryl Hydrocarbon Receptor (2) Atg8/LC3 (1) Autophagy (26) Bacterial (20) BCL6 (1) Bcr-Abl (3) BCRP (1) Biochemical Assay Reagents (1) c-Fms (1) Cadherin (1) Calcium Channel (5) Caspase (1) Claudin (3) COX (10) CXCR (2) Cytochrome P450 (6) Dipeptidyl Peptidase (3) DNA/RNA Synthesis (4) Dopamine Receptor (8) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (8) EGFR (6) Elastase (1) Endogenous Metabolite (20) Estrogen Receptor/ERR (2) FAAH (1) Factor Xa (1) Ferroptosis (3) FGFR (3) FKBP (1) Folate Receptor (FR) (1) Fungal (4) Glucocorticoid Receptor (1) GnRH Receptor (1) HCV (4) HCV Protease (1) Herbicide (1) Histamine Receptor (11) HIV (6) HIV Integrase (1) HIV Protease (1) HMG-CoA Reductase (HMGCR) (2) HSV (1) IFNAR (8) Imidazoline Receptor (2) Influenza Virus (3) Interleukin Related (17) Isotope-Labeled Compounds (196) Itk (1) JAK (2) LDLR (1) Leukotriene Receptor (1) Liposome (1) mAChR (1) MAP4K (2) MDM-2/p53 (1) MEK (1) MHC (1) Microtubule/Tubulin (3) Mineralocorticoid Receptor (1) Mitochondrial Metabolism (1) Mitophagy (1) MMP (1) mTOR (2) Mucin (1) Na+/K+ ATPase (1) Neurokinin Receptor (1) NF-κB (1) NO Synthase (1) Notch (3) Nuclear Factor of activated T Cells (NFAT) (1) Nucleoside Antimetabolite/Analog (1) Opioid Receptor (1) Orexin Receptor (OX Receptor) (1) P2Y Receptor (1) p38 MAPK (1) Parasite (10) PARP (1) PD-1/PD-L1 (11) PDGFR (6) Phosphatase (1) Phosphodiesterase (PDE) (2) PI3K (2) PKC (1) Potassium Channel (3) Progesterone Receptor (2) PROTACs (3) Proton Pump (3) PSMA (2) Quinone Reductase (1) Raf (3) Reactive Oxygen Species (ROS) (2) Reference Standards (1) RET (1) Reverse Transcriptase (1) ROR (1) SARS-CoV (8) Serotonin Transporter (1) Small Interfering RNA (siRNA) (11) Sodium Channel (2) Src (3) STAT (1) TGF-beta/Smad (1) Thrombin (1) Thyroid Hormone Receptor (2) TNF Receptor (15) Toll-like Receptor (TLR) (1) Topoisomerase (2) Transmembrane Glycoprotein (6) VD/VDR (1) VEGFR (7) VKOR (1)
By Research Areas:	Cancer (155) Cardiovascular Disease (18) Endocrinology (20) Infection (40) Inflammation/Immunology (94) Metabolic Disease (23) Neurological Disease (35)
Click Chemistry:	Azide (1)
Oligonucleotides:	CpG ODNs (1) Rat Pre-designed siRNA Sets (3) Cationic Lipids (1) Mouse Pre-designed siRNA Sets (4) Human Pre-designed siRNA Sets (4) siRNAs (11)

370

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

MCE Kits

116

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

215

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: CD3 CD1 CD38 CD28 CD19 CD20 CD22 Transferrin Receptor P-selectin CD6 CD2 CD276/B7-H3 CD73 c-Kit LAG-3 L-Selectin CTLA-4 CD47 ALCAM/CD166 Neprilysin E-Selectin Scavenger Receptor Class B type I (SR-BI） FLT3 Tim3 CD44 Anaplastic lymphoma kinase (ALK) CD74 Human leukocyte immunoglobulin (Ig)-like receptors (LILR) P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99392

Teclistamab JNJ-7957; JNJ-64007957; Tecvayli	CD3	Cancer
Teclistamab is a human bispecific antibody to BCMA and *CD3* that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .

HY-P99601

Cevostamab BFCR 4350A; RG 6160; RO 7187797	CD3	Neurological Disease Cancer
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as *CD3* on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .

HY-P99033

Mosunetuzumab 1 Publications Verification BTCT-4465A; RG-7828; RO7030816	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and *CD3* (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99024

Glofitamab 1 Publications Verification RO7082859; RG-6026	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for *CD3* on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) ^[3] .

HY-P99592

Solitomab AMG 110	CD3	Cancer
Solitomab (AMG 110) is a bispecific *anti-CD3* and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .

HY-P99931

Epcoritamab 1 Publications Verification GEN3013	CD3 CD20	Cancer
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 ⁺ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .

HY-P990688

Xaluritamig AMG-509	CD3	Cancer
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a K_d of 27.6 nM for human *CD3ε. Xaluritamig binds to CD3ε* via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 ⁺ T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in *STEAP1×CD3* XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma ^[3].

HY-P991028

Surovatamig AZD0486; TNB-486	CD3 CD19 Interleukin Related TNF Receptor IFNAR	Cancer
Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .

HY-P990864

*Anti-CD3* Antibody (OKT-3)**	CD3	Inflammation/Immunology
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a κ antibody inhibitor, targeting to human *CD3. Anti-CD3* Antibody (OKT-3) decreases T cells. Anti-CD3 Antibody (OKT-3) can be used for the research of immunology, such as graft-versus-host disease ^[3].

HY-P99539

Ubamatamab REGN4018	CD3	Cancer
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and *CD3*. Ubamatamab demonstrates potent antitumor activity .

HY-P99394

Talquetamab 1 Publications Verification JNJ-64407564	CD3	Cancer
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and *CD3* to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .

HY-P99802

Pasotuxizumab 1 Publications Verification BAY 2010112; AMG 212; MT112	CD3	Cancer
Pasotuxizumab (BAY 2010112) is a PSMA and *CD3* bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_Ds of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .

HY-P99762

Obrindatamab 1 Publications Verification MGD009	CD3	Cancer
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human *CD3* monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99517

Voxalatamab JNJ-63898081; JNJ-081	CD3 PSMA	Cancer
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and *CD3. Voxalatamab attacks PSMA*-expressing tumor cells by activating T cells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .

HY-P990932

Obrixtamig BI 764532; OBT 620	CD3	Cancer
Obrixtamig (BI 764532; OBT 620) is an *CD3E/DLL3*-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibody. Obrixtamig is a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager. Obrixtamig can be used for research of DLL3-positive small cell lung cancer .

HY-P99011

Cibisatamab 2 Publications Verification	CD3	Cancer
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and *CD3* on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .

HY-P99896

Runimotamab BTRC-4017A; RG-6194	EGFR CD3	Cancer
Runimotamab (BTRC-4017A) is a HER2 and *CD3* T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3* T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .

HY-P990717

Brenetafusp IMC-F106C	CD3	Cancer
Brenetafusp is a TCR/anti-CD3 bispecific fusion protein, consisting of a TCR targeting the PRAME peptide and an anti-CD3 scFv effector domain. Brenetafusp redirects *CD3* ⁺ T cells to kill PRAME ⁺ tumor cells. Brenetafusp can be used in research related to cutaneous melanoma, non-small cell lung cancer, ovarian cancer, endometrial cancer, triple-negative breast cancer, and small cell lung cancer .

HY-P99350

Gresonitamab 1 Publications Verification AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets *CD3*-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-P99038

Odronextamab REGN1979	CD20 CD3	Inflammation/Immunology Cancer
Odronextamab is a stable humanized IgG4 CD20 × *CD3* bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .

HY-P99948

Etevritamab AMG-596	EGFR CD3	Neurological Disease Cancer
Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and *CD3. Etevritamab simultaneously binds CD3* on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .

HY-P99152

Muromonab Muromanab-CD3	CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the *CD3* antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients ^[3] .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology Cancer
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational *CD123/CD3* bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and *CD3* in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P990925

Linclatamig BLYG8824A; RG6286	CD3	Inflammation/Immunology
Linclatamig (BLYG8824A) is a humanized IgG1 T-cell engaging bispecific antibody (TCB) targeting LY6G6D and *CD3. Linclatamig can bind to LY6G6D and CD3-positive* T cells, forming an immunological synapse to promote T cell-mediated killing of LY6G6D-positive cells. Linclatamig can be used in tumor research .

HY-P99430

Alnuctamab EM901; CC-93269	CD3	Inflammation/Immunology Cancer
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and *CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA* expressed on the surface of myeloma cells and *CD3* molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) ^[3].

HY-P991731

Alveltamig ZG006	CD3 Notch	Neurological Disease Cancer
Alveltamig (ZG006) is a trispecific T cell engager targeting Delta-like ligand 3 (DLL3)/CD3, mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the researches of small cell lung cancer and neuroendocrine carcinoma .

HY-P99199

Foralumab NI-0401	CD3	Inflammation/Immunology
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the *CD3*. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .

HY-P990980

Cizutamig CND-106; EMB-06	CD3	Inflammation/Immunology Cancer
Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and *CD3*. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .

HY-P991490

ISB2001	CD38 CD3 TNF Receptor	Cancer
ISB2001 is a trispecific antibody targeting CD38, *CD3* and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma .

HY-P9989

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) ^[3].

HY-P990802

*Anti-Mouse CD3ε Antibody (145-2C11)*	CD3	Metabolic Disease Inflammation/Immunology
Anti-Mouse CD3ε Antibody (145-2C11) is an orally active anti-mouse *CD3ε* IgG1 monoclonal antibody. Anti-Mouse CD3ε Antibody (145-2C11) can inhibit the proliferation of effector T cells and improve the function of regulatory T cells (Tregs). Anti-Mouse CD3ε Antibody (145-2C11) relieves inflammatory response by inhibiting the production of pro-inflammatory cytokines and increasing the secretion of anti-inflammatory factors. Anti-Mouse CD3ε Antibody (145-2C11) can be used for researches on metabolic and immune system conditions such as diabetes and lupus. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305) .

HY-P990981

Clesitamig ALPS-12; RG-6524; RO 7616789	CD3	Inflammation/Immunology Cancer
Clesitamig (ALPS-12) is a trispecific T cell engager with two *CD3/CD137* dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC) .

HY-P991526

M701	CD3	Cancer
M701 is a T-cell engager bispecific humanized antibody targeting epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). M701 binds to EpCAM on tumor cells and *CD3* on T cells, thereby linking the two cell populations to achieve targeted cytotoxicity and T cell-mediated cytotoxicity. M701 is applicable to research related to advanced epithelial solid tumors .

HY-P99124

*Anti-Mouse CD3* Antibody (17A2)** 1 Publications Verification	CD3	Inflammation/Immunology
Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .

HY-P99910

Eluvixtamab AMG-330	CD3 Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and *CD3* on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia .

HY-P990104

Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)	Notch	Inflammation/Immunology Cancer
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P99757

Nivatrotamab Hu3F8-BsAb	CD2 CD3	Cancer
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .

HY-P99523

Vepsitamab AMG 199	CD3	Cancer
Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and *CD3. Vepsitamab directs CD3-positive* cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer .

HY-P990785

Etentamig ABBV-383; TNB 383B	CD3	Cardiovascular Disease Inflammation/Immunology Cancer
Etentamig is a BCMA × *CD3* bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein *CD3* complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .

HY-P99958

Vixtimotamab AMV-564; TandAb T564	Transmembrane Glycoprotein	Cancer
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human *CD3* antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .

HY-126328

PKC-theta inhibitor 1	PKC Interleukin Related	Inflammation/Immunology
PKC-theta inhibitor 1 is an orally active and selective ATP-competitive inhibitor of Protein Kinase Cθ (PKCθ), with a K_i value of 6 nM. PKC-theta inhibitor 1 inhibits T-cell-mediated inflammatory responses by suppressing the release of proinflammatory cytokines (IL-2 IC₅₀ = 0.21 μM in anti-CD3/CD28-stimulated PBMCs; IL-17 IC₅₀ = 1 μM in CD3/CD28-stimulated Th17 cells) PKC-theta inhibitor 1 significantly reduces symptoms in mice with ongoing experimental autoimmune encephalomyelitis (EAE). PKC-theta inhibitor 1 can be used for the study of T-cell-mediated inflammatory diseases such as multiple sclerosis .

HY-P990095

Vonsetamig REGN5459	CD3 TNF Receptor	Cancer
Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and *CD3*. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma .

HY-P99776

Plamotamab XmAb-13676	CD20 CD3	Cancer
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds *CD3* and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 ⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) ^[3] .

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Emfizatamab (GNC-038) is a monoclonal antibody against *CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3* and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .

HY-103316

trans-Ned 19	Calcium Channel	Cardiovascular Disease Inflammation/Immunology
trans-Ned 19 is a NAADP antagonist and TPC blocker. trans-Ned 19 suppresses the calcium signal and the rat aorta relaxation in response to low histamine concentrations. trans-Ned 19 increases the spontaneous acrosome reaction rate, alleviates anti-CD3 mAb-induced intestinal inflammation, and improves kidney damage in mice with nephrotoxic serum nephritis ^[3] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N10445

Maydispenoid A	Microorganisms Terpenoids Sesquiterpenes Source Classification	CD28 CD3
Maydispenoid A is a potent immunosuppressor. Maydispenoid A can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .

HY-N10446

Maydispenoid B	Microorganisms Terpenoids Sesquiterpenes Source Classification	CD28 CD3
Maydispenoid B is a potent immunosuppressor. Maydispenoid B can inhibit anti-CD3/anti-CD28 mAbs activated and lipopolysaccharide activated murine splenocyte proliferation .

Cat. No.	Product Name	Chemical Structure

HY-17508S

Clarithromycin-13C,d3
Clarithromycin- ¹³C,d₃ is the deuterium and ¹³C labeled Clarithromycin .

HY-50667S

Apixaban-13C,d3
Apixaban- ¹³C,d₃ (BMS-562247-01- ¹³C,d₃) is a deuterium and ¹³C labeled Apixaban (HY-50667). Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-143996S

Mevalonic acid-13C,d3 sodium
Mevalonic acid- ¹³C,d₃ (sodium) is the ¹³C- and deuterium labeled Mevalonic acid .

HY-10219S1

Rapamycin-13C,d3
Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-16767S1

Doravirine-13C,d3
Doravirine-13C,d3 (MK-1439-13C,d3) is the deuterium labeled Doravirine (HY-16767). Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC₅₀s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and K103N and Y181C reverse transcriptase mutants, respectively .

HY-143778S

Clavulanic acid methyl ester-13C,d3
Clavulanic acid methyl ester- ¹³C,d₃ is the deuterium and ¹³C labeled Clavulanic acid methyl ester .

HY-W653977

Chlortetracycline-13C,d3 hydrochloride

Chlortetracycline-13C,d3 hydrochloride (7-Chlorotetracycline-13C,d3 hydrochloride) is the 13C- and deuterium labeled Chlortetracycline hydrochloride (HY-B1327). Chlortetracycline hydrochloride is an orally active, selective antibiotic, that inhibits methanogenic bacteria through inhibition of bacterial protein synthesis. Chlortetracycline hydrochloride is a specific and potent calcium ionophore antibiotic, that inhibits binding of aminoacyl-tRNA to ribosomes ^[3] .

HY-B0330S2

Levofloxacin-13C,d3
Levofloxacin- ¹³C,d₃ is the ¹³C- and deuterium labeled Levofloxacin.

HY-17506S1

Azithromycin-13C,d3
Azithromycin- ¹³C,d₃ is the deuterium and ¹³C labeled Azithromycin .

HY-66011AS4

Moxifloxacin-13C,d3 hydrochloride
Moxifloxacin- ¹³C,d₃ hydrochloride (BAY 12-8039- ¹³C,d₃) is ¹³C and deuterated labeled Moxifloxacin (HY-66011A). Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.

HY-17413S1

Zidovudine-13C,d3
Zidovudine- ¹³C,d₃ is the ¹³C- and deuterium labeled Zidovudine. Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection.

HY-W102449S

4-Acetyl-N-methylaniline-13C,d3
4-Acetyl-N-methylaniline- ¹³C,d₃ (1-(4-(Methylamino)phenyl)ethanone- ¹³C,d₃ ) is a ¹³C and deuterated isotope of 4-Acetyl-N-methylaniline .

HY-W753602

Acetamiprid-N-desmethyl-13C,d3
Acetamiprid-N-desmethyl- ¹³C,d3 is the ¹³C and deuterium labeled isotope of Acetamiprid-N-desmethyl( ¹³C,d3)(HY-B0823).Acetamiprid is a nAChR agonist that has been implicated in neuromuscular and reproductive disorders.

HY-W778270

2-Oxo clopidogrel-13C,d3 hydrochloride
2-Oxo clopidogrel- ¹³C,d₃ hydrochloride is the deuterium and ¹³C-labeled (±)-2-Oxo clopidogrel hydrochloride (HY-W585947).

HY-I0459S

Apixaban acid-13C,d3
Apixaban acid- ¹³C,d₃ is the deuterium and ¹³C labeled Apixaban acid .

HY-121259S

Doxorubicinol-13C,d3 TFA
Doxorubicinol- ¹³C,d₃ (TFA) is the deuterium and ¹³C labeled Doxorubicinol TFA .

HY-W777749

Methoxsalen-13C,d3
Methoxsalen- ¹³C,d₃ (8-Methoxypsoralen- ¹³C,d₃) is the deuterium and ¹³C-labeled Methoxsalen (HY-30151). Methoxsalen (8-Methoxypsoralen) is a furanocoumarin compound used in psoralen, used in studies of psoriasis, eczema, vitiligo and some sun-exposed cutaneous lymphomas, and is a P450 inhibitor.

HY-Z2483S

Clopidogrel-MP endo derivative-13C,d3
Clopidogrel-MP endo derivative- ¹³C,d₃ is the deuterium and ¹³C labeled Clopidogrel-MP endo derivative .

HY-138199S

Omeprazole sulfone N-oxide-13C,d3
Omeprazole sulfone N-oxide- ¹³C,d₃ is the deuterium and ¹³C labeled Omeprazole sulfone N-Oxide .

HY-B0251S1

Eplerenone-13C,d3

Eplerenone- ¹³C,d₃ (Epoxymexrenone- ¹³C,d₃) is ¹³C labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC₅₀ value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV) .

HY-15651S

Alvelestat-13C,d3
Alvelestat- ¹³C,d₃ (AZD9668- ¹³C,d₃) is ¹³C-labeled Alvelestat (HY-15651) .

HY-B0462S

Azelastine-13C,d3 hydrochloride
Azelastine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Azelastine hydrochloride. Azelastine- ¹³C,d₃ (hydrochloride), an antihistamine, is a potent and selective histamine 1 (H1) antagonist. Azelastine- ¹³C,d₃ (hydrochloride) can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2 ^[3] .

HY-17016S3

Oseltamivir-13C,d3 phosphate
Oseltamivir- ¹³C,d₃ (phosphate) (GS 4104- ¹³C,d₃ (phosphate)) is ¹³C labeled Oseltamivir (phosphate). Oseltamivir phosphate (GS 4104) is a neuraminidase inhibitor recommended for the treatment and prophylaxis of influenza A and B.

HY-W769734

N-Acetylneuraminic Acid-13C,d3
N-Acetylneuraminic Acid- ¹³C,d₃ (N-Acetyl-β-D-neuraminic acid- ¹³C,d₃) is the deuterium labeled and ¹³C-labeled N-Acetyl-β-D-neuraminic acid (HY-75278).

HY-40354S2

Tofacitinib-13C,d3
Tofacitinib- ¹³C,d₃ (Tasocitinib- ¹³C,d₃) is ¹³C labeled Tofacitinib. Tofacitinib is an orally available *JAK3/2/1* inhibitor with IC₅₀s of 1, 20, and 112 nM, respectively.

HY-W754370

Methyltriphenylphosphonium bromide-13C,d3
Methyltriphenylphosphonium bromide- ¹³C,d₃ (Phosphonium, methyltriphenyl-, bromide (8CI,9CI)- ¹³C,d₃) is the deuterium and ¹³C labeled Methyltriphenylphosphonium bromide (HY-Y1033).

HY-10158S1

Bosutinib-13C,d3
Bosutinib- ¹³C,d₃ (SKI-606- ¹³C,d₃) is ¹³C labeled Bosutinib. Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC₅₀ of 1.2 nM and 1 nM, respectively .

HY-B0373S

Tiopronin-13C,d3
Tiopronin- ¹³C,d₃ is deuterium labeled Tiopronin.

HY-B0157S

Ketotifen-13C,d3
Ketotifen- ¹³C,d₃ is deuterium labeled Ketotifen.

HY-13318S1

Oseltamivir acid-13C,d3
Oseltamivir acid-13C,d3 (GS 4071-13C,d3; Ro 64-0802-13C,d3) is a 13C- and deuterium-labeled Oseltamivir acid (HY-13318). Oseltamivir acid is the active metabolite of Oseltamivir phosphate and inhibits influenza virus neuraminidase (IC₅₀=2 nM). Oseltamivir acid is orally active and can be used to study influenza A/B infections ^[3] .

HY-W768856

Artemether-13C,d3
Artemether- ¹³C,d₃ (Dihydroqinghaosu methyl ether- ¹³C,d₃) is the deuterium and ¹³C-labeled Artemether (HY-N0402). Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria .

HY-W778023

(R)-2-(3-Benzoylphenyl)propanoic acid-13C,d3
(R)-2-(3-Benzoylphenyl)propanoic acid- ¹³C,d₃ ((R)-(-)-Ketoprofen- ¹³C,d₃) is the deuterium labeled and ¹³C-labeled Ketoprofen-d₃-1 (HY-W322573S).

HY-18252S

Avanafil-13C,d3
Avanafil- ¹³C,d₃ is the ¹³C- and deuterium labeled Avanafil.

HY-B0740S1

Cyclobenzaprine-13C,d3 hydrochloride
Cyclobenzaprine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Cyclobenzaprine (hydrochloride).

HY-B0192S1

Alfuzosin-13C,d3
Alfuzosin- ¹³C,d₃ is the ¹³C- and deuterium labeled Alfuzosin.

HY-B0164S

Mizolastine-13C,d3
Mizolastine- ¹³C,d₃ is the ¹³C- and deuterium labeled Mizolastine.

HY-W778236

Norflurazon-13C,d3
Norflurazon- ¹³C,d₃ (SAN 9789- ¹³C,d₃) is the deuterium and ¹³C-labeled Norflurazon (HY-114849). Norflurazon (SAN 9789) is a bleaching herbicide. Norflurazon can block carotenoid biosynthesis by inhibiting phytoene desaturase activity .

HY-17410S2

Iloperidone-13C,d3
Iloperidone- ¹³C,d₃ (HP 873- ¹³C,d₃) is ¹³C labeled Iloperidone. Iloperidone (HP 873) is a D₂/5-HT₂ receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms .

HY-W777978

2-Bromo-3'-methoxyacetophenone-13C,d3
2-Bromo-3'-methoxyacetophenone- ¹³C,d₃ (α-Bromo-3'-methoxyacetophenone- ¹³C,d₃) is the deuterium and ¹³C labeled 2-Bromo-3'-methoxyacetophenone (HY-W004800).

HY-W767936

Moxonidine-13C,d3
Moxonidine- ¹³C,d₃ (BDF5895- ¹³C,d₃) is the ¹³C-labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an imidazoline type 1 receptor (I1-R) selective agonist and antihypertensive agent.

HY-W751082

H-N-Me-Ala-OH-13C,d3
H-N-Me-Ala-OH- ¹³C,d₃ (N-Methyl-L-alanine- ¹³C,d₃) is the deuterium and ¹³C labeled H-N-Me-Ala-OH (HY-W015926). H-N-Me-Ala-OH is an alanine derivative .

HY-13577S

Oclacitinib-13C-d3
Oclacitinib- ¹³C-d₃ is the deuterium and ¹³C labeled Oclacitinib .

HY-17583S1

Griseofulvin-13C,d3
Griseofulvin- ¹³C,d₃ is the ¹³C- and deuterium labeled Griseofulvin .

HY-14151S

Prucalopride-13C,d3
Prucalopride- ¹³C,d₃ is the ¹³C- and deuterium labeled Prucalopride .

HY-144248S

Levomedetomidine-13C,d3 hydrochloride
Levomedetomidine- ¹³C,d₃ (hydrochloride) is the ¹³C- and deuterium labeled Levomedetomidine .

HY-144148S

Pyroxsulam-13C,d3
Pyroxsulam- ¹³C,d₃ is the ¹³C- and deuterium labeled Pyroxsulam .

HY-143848S

Tadalafil-13C,d3
Tadalafil- ¹³C,d₃ is the deuterium and ¹³C labeled Tadalafil .

HY-12651AS

Primaquine-13C,d3
Primaquine- ¹³C,d₃ is the deuterium and ¹³C labeled Primaquine .

HY-10250S

Triciribine phosphate-13C,d3
Triciribine phosphate-- ¹³C,d₃ is the deuterium and ¹³C labeled Triciribine phosphate .

HY-143786S

Tazobactum ester-13C,d3
Tazobactum ester- ¹³C,d₃ is the deuterium and ¹³C labeled Tazobactum ester .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks